Skip to main content
Figure 3 | BMC Gastroenterology

Figure 3

From: Mucosal gene therapy using a pseudotyped lentivirus vector encoding murine interleukin-10 (mIL-10) suppresses the development and relapse of experimental murine colitis

Figure 3

The time course of clinical changes of 3% dextran sulfate sodium (DSS) colitis with/without lentivirus vector (LV) encoding mouse interleukin 10 (mIL-10). Mice were treated with 3% DSS from Days 1–7 and 18–24. Four treatment groups (n = 8 mice per group) were (i) a control group who did not receive DSS or an LV (NC), (ii) a group who received DSS + a mock plasmid control (mock), (iii) a group who received DSS + a single dose of the mIL-10 LV on Day 3 (LV(1)), and (iv) a group who received DSS + doses of the mIL-10 LV on Days 3 and 20 (LV(2)).

Back to article page